Inhibition of neuronal cell mitochondrial complex i with rotenone increases lipid β-oxidation, supporting acetyl-coenzyme a levels

Journal of Biological Chemistry

Volumn 289, Issue 39, 2014, Pages 26895-26903

  Worth, Andrew J ^a   Basu, Sankha S ^a   Snyder, Nathaniel W ^a   Mesaros, Clementina ^a   Blair, Ian A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CARBOXYLATION; CHAINS; FATTY ACIDS; METABOLISM; PHYSIOLOGY;

HUMAN POPULATION; LIPID METABOLISMS; MECHANISTIC LINK; MITOCHONDRIAL COMPLEX; NATURALLY OCCURRING; NEUROBLASTOMA CELLS; NEURONAL DAMAGE; RODENT MODELS;

FLAVONOIDS;

ACETYL COENZYME A; GLUTAMINE; MEDIUM CHAIN ACYL COENZYME A; OCTANOIC ACID; PALMITIC ACID; PALMITOYL COENZYME A; PALMITOYLCARNITINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; UNCLASSIFIED DRUG; FATTY ACID; UNCOUPLING PROTEIN;

ARTICLE; CARBOXYLATION; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; LIPID METABOLISM; LIPOGENESIS; NEUROBLASTOMA CELL; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; METABOLISM; NERVE CELL; OXIDATION REDUCTION REACTION; TUMOR CELL LINE;

ACETYL COENZYME A; CELL LINE, TUMOR; ELECTRON TRANSPORT COMPLEX I; FATTY ACIDS; GLUTAMINE; HUMANS; NEURONS; OXIDATION-REDUCTION; PALMITOYL COENZYME A; ROTENONE; UNCOUPLING AGENTS;

EID: 84907572376     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.591354     Document Type: Article

References (47)

1. Hartley, A., Stone, J. M., Heron, C., Cooper, J. M., and Schapira, A. H. (1994) Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J. Neurochem. 63, 1987-1990
2. Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., Marras, C., Bhudhikanok, G. S., Kasten, M., Chade, A. R., Comyns, K., Richards, M. B., Meng, C., Priestley, B., Fernandez, H. H., Cambi, F., Umbach, D. M., Blair, A., Sandler, D. P., and Langston, J. W. (2011) Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 119, 866-872
3. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306
4. Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., and Greenamyre, J. T. (2009)Ahighly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 34, 279-290
5. Kim, K. Y., and Sack, M. N. (2012) Parkin in the regulation of fat uptake and mitochondrial biology: emerging links in the pathophysiology of Parkinson's disease. Curr. Opin. Lipidol. 23, 201-205
6. Exner, N., Lutz, A. K., Haass, C., and Winklhofer, K. F. (2012) Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 31, 3038-3062
7. Pickrell, A. M., Pinto, M., and Moraes, C. T. (2013) Mouse models of Parkinson's disease associated with mitochondrial dysfunction. Mol. Cell. Neurosci. 55, 87-94
8. Subramaniam, S. R., and Chesselet, M. F. (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog. Neurobiol. 106-107, 17-32
9. Jenner, P. (2003) Oxidative stress in Parkinson's disease. Ann. Neurol. 53, Suppl. 3, S26-S36
10. Henchcliffe, C., Shungu, D. C., Mao, X., Huang, C., Nirenberg, M. J., Jenkins, B. G., and Beal, M. F. (2008) Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Ann. N.Y. Acad. Sci. 1147, 206-220
11. Li, N., Ragheb, K., Lawler, G., Sturgis, J., Rajwa, B., Melendez, J. A., and Robinson, J. P. (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 278, 8516-8525
12. Shamoto-Nagai, M., Maruyama, W., Kato, Y., Isobe, K., Tanaka, M., Naoi, M., and Osawa, T. (2003) An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J. Neurosci. Res. 74, 589-597
13. Weber, C. A., and Ernst, M. E. (2006) Antioxidants, supplements, and Parkinson's disease. Ann. Pharmacother. 40, 935-938
14. Xie, H. R., Hu, L. S., and Li, G. Y. (2010) SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin. Med. J. (Engl.) 123, 1086-1092
15. Basu, S. S., and Blair, I. A. (2011) Rotenone-mediated changes in intracellular coenzymeAthioester levels: implications for mitochondrial dysfunction. Chem. Res. Toxicol. 24, 1630-1632
16. Zhang, G. F., Sadhukhan, S., Tochtrop, G. P., and Brunengraber, H. (2011) Metabolomics, pathway regulation, and pathway discovery. J. Biol. Chem. 286, 23631-23635
17. Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., Kelleher, J. K., Vander Heiden, M. G., Iliopoulos, O., and Stephanopoulos, G. (2012) Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384
18. Mullen, A. R., Wheaton, W. W., Jin, E. S., Chen, P. H., Sullivan, L. B., Cheng, T., Yang, Y., Linehan, W. M., Chandel, N. S., and DeBerardinis, R. J. (2012) Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385-388
19. Basu, S. S., Mesaros, C., Gelhaus, S. L., and Blair, I. A. (2011) Stable Isotope labeling by essential nutrients in cell culture for preparation of labeled coenzyme A and its thioesters. Anal. Chem. 83, 1363-1369
20. Singh, G., Gutierrez, A., Xu, K., and Blair, I. A. (2000) Liquid chromatography/ electron capture atmospheric pressure chemical ionization/mass spectrometry: analysis of pentafluorobenzyl derivatives of biomolecules and drugs in the attomole range. Anal. Chem. 72, 3007-3013
21. Snyder, N. W., Khezam, M., Mesaros, C. A., Worth, A., and Blair, I. A. (2013) Untargeted metabolomics from biological sources using ultraperformance liquid chromatography-high resolution mass spectrometry (UPLC-HRMS). J. Vis. Exp. 75, e50433
22. Basu, S. S., and Blair, I. A. (2012) SILEC: a protocol for generating and using isotopically labeled coenzyme A mass spectrometry standards. Nat. Protoc. 7, 1-12
23. Lee, S. H., and Blair, I. A. (2007) Targeted chiral lipidomics analysis by liquid chromatography electron capture atmospheric pressure chemical ionization mass spectrometry (LC-ECAPCI/MS). Methods Enzymol. 433, 159-174
24. DeBerardinis, R. J., and Cheng, T. (2010) Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313-324
25. Lu, W., Pelicano, H., and Huang, P. (2010) Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell 18, 199-200
26. Daye, D., and Wellen, K. E. (2012) Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 23, 362-369
27. Mally, J., Szalai, G., and Stone, T. W. (1997) Changes in the concentration of amino acids in serum and CSF of patients with Parkinson's disease. J. Neurol. Sci. 151, 159-162
28. Du, Q., Wang, T., Wang, Z., Jiang, X., and Wang, L. (April 25, 2014) Rapid determination of glutamine in human plasma by high-performance liquid chromatographic-tandem mass spectrometry and its application in pharmacokinetic studies. J. Chromatogr. Sci. 10.1093/chromsci/bmu022
29. Des Rosiers, C., Fernandez, C. A., David, F., and Brunengraber, H. (1994) Reversibility of the mitochondrial isocitrate dehydrogenase reaction in the perfused rat liver. Evidence from isotopomer analysis of citric acid cycle intermediates. J. Biol. Chem. 269, 27179-27182
30. Wise, D. R., and Thompson, C. B. (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35, 427-433
31. Pieczenik, S. R., and Neustadt, J. (2007) Mitochondrial dysfunction and molecular pathways of disease. Exp. Mol. Pathol. 83, 84-92
32. Varçin, M., Bentea, E., Michotte, Y., and Sarre, S. (2012) Oxidative stress in genetic mouse models of Parkinson's disease. Oxid. Med. Cell. Longev. 2012, 624925
33. Zhou, C., Huang, Y., and Przedborski, S. (2008) Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N.Y. Acad. Sci. 1147, 93-104
34. Taylor, J. M., Main, B. S., and Crack, P. J. (2013) Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem. Int. 62, 803-819
35. Beal, M. F. (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31, 119-130
36. Hauser, D. N., and Hastings, T. G. (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol. Dis. 51, 35-42
37. Kim, K. Y., Stevens, M. V., Akter, M. H., Rusk, S. E., Huang, R. J., Cohen, A., Noguchi, A., Springer, D., Bocharov, A. V., Eggerman, T. L., Suen, D. F., Youle, R. J., Amar, M., Remaley, A. T., and Sack, M. N. (2011) Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J. Clin. Invest. 121, 3701-3712
38. Fan, J., Kamphorst, J. J., Rabinowitz, J. D., and Shlomi, T. (2013) Fatty acid labeling from glutamine in hypoxia can be explained by isotope exchange without net reductive isocitrate dehydrogenase (IDH) flux. J. Biol. Chem. 288, 31363-31369
39. Reitman, Z. J., Duncan, C. G., Poteet, E., Winters, A., Yan, L. J., Gooden, D. M., Spasojevic, I., Boros, L. G., Yang, S. H., and Yan, H. (2014) Cancerassociated isocitrate dehydrogenase 1 (IDH1) R132H mutation and D-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J. Biol. Chem. 289, 23318-23328
40. Lowther, J., Naismith, J. H., Dunn, T. M., and Campopiano, D. J. (2012) Structural, mechanistic and regulatory studies of serine palmitoyltransferase. Biochem. Soc. Trans. 40, 547-554
41. Kamphorst, J. J., Cross, J. R., Fan, J., de Stanchina, E., Mathew, R., White, E. P., Thompson, C. B., and Rabinowitz, J. D. (2013) Hypoxic and Rastransformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl. Acad. Sci. U.S.A. 110, 8882-8887
42. Gameiro, P. A., Laviolette, L. A., Kelleher, J. K., Iliopoulos, O., and Stephanopoulos, G. (2013) Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle. J. Biol. Chem. 288, 12967-12977
43. Zhang, Z., Tan, M., Xie, Z., Dai, L., Chen, Y., and Zhao, Y. (2011) Identification of lysine succinylation as a new post-translational modification. Nat. Chem. Biol. 7, 58-63
44. Newman, J. C., He, W., and Verdin, E. (2012) Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. J. Biol. Chem. 287, 42436-42443
45. Plaitakis, A., and Shashidharan, P. (2000) Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J. Neurol. 247, Suppl. 2, II25-II35
46. Chassain, C., Bielicki, G., Donnat, J. P., Renou, J. P., Eschalier, A., and Durif, F. (2005) Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic 13C NMS study in the rat. Exp. Neurol. 191, 276-284
47. Emadi, A., Jun, S. A., Tsukamoto, T., Fathi, A. T., Minden, M. D., and Dang, C. V. (2014) Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp. Hematol. 42, 247-251